Functional experiments conducted in two OC cell lines revealed that both gene silencing and pharmacological inhibition of CD117 kinase activity with imatinib reduced significantly their sphere-forming potential [112], pointing to CD117 as a possible therapeutic target in the context of OCSC. Here, KIT is linked to oral cavity squamous cell carcinoma.